Skip to main content
SpringerLink
Log in

Neuroleptika, Antidepressiva und Lithium — Synopsis und Perspektiven

  • Conference paper
Psychopharmaka heute

  • 50 Accesses

Zusammenfassung

Die pharmakologischen und neurobiochemischen Wirkungen der Neuroleptika, Antidepressiva und des Lithiums sind schon vielfach beschrieben worden, und zwar in jedem beliebigen Umfang. Zentralpunkte der Beschreibungen sind hie und da die pharmakologischen Wirkungen gewesen, oder auch die neurobiochemischen Effekte, mit besonderer Bedeutung der tierexperimentellen Aspekte, oder dann die klinischen Befunde. Selten aber sind alle drei Klassen der oben erwähnten Psychopharmaka in kurzer, einheitlicher Form mit Betonung der biologischen Effekte und Ausblick auf die heutigen Forschungsrichtungen vorgestellt worden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D1 receptor: Clozapine and fluperlapine may preferentially laben an adenylate cyclase-coupled state of the D1 receptor. J Neurochem 47: 1822–1831

    Article  PubMed  CAS  Google Scholar 

  • Andersen PH, Nielsen EB, Gronvald FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. Eur J Pharmacol 120: 143–144

    Article  PubMed  CAS  Google Scholar 

  • Avissar S, Schreiber G, Danon A, Belmaker RH (1988) Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331: 440–442

    Article  PubMed  CAS  Google Scholar 

  • Bansal VS, Inhorn RC, Mejerus PW (1987) The metabolism of inositol 1,3,4-trisphosphate to inositol 1,3-bisphosphate. J Biol Chem 262: 9444–9447

    PubMed  CAS  Google Scholar 

  • Batty I, Nahorski SR (1987) Lithium inhibits muscarinic-receptor-stimulated inositol tetrakisphosphate accumulation in rat cerebral cortex. Biochem J 247: 797–800

    PubMed  CAS  Google Scholar 

  • Berridge MJ, Irvine RF (1984) Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 312: 315–321

    Article  PubMed  CAS  Google Scholar 

  • Berridge MJ, Downes CP, Hanley MR (1982) Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary gland. Biochem J 206: 587–595

    PubMed  CAS  Google Scholar 

  • Bertolino A, Crippa D, Di Dio S et al. (1988) Rolipram versus imipramine in patients with major, „minor“ or atypical depressive disorder: A double blind double dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3: 245–253

    Article  PubMed  CAS  Google Scholar 

  • Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO-inhibitors: Brofaramine and moclobemide vs. irreversible inhibitors. J Neural Transm [Suppl] in press

    Google Scholar 

  • Bieck PR, Firkusny L, Schick C et al. (1989) Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45: 260–269

    Article  PubMed  CAS  Google Scholar 

  • Bischoff S, Christen P, Vassout A (1988) Blockade of hippocampal dopamine ( DA) receptors: A tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry 12: 455–467

    Google Scholar 

  • Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G (1988) Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238: 2–6

    Article  PubMed  CAS  Google Scholar 

  • Breyer-Pfaff U, Gaertner JH (1987) Antidepressiva: Pharmakologie, therapeutischer Einsatz and Klinik der Depression. Medizinisch-pharmakologisches Konpendium, Bd 5. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  • Bürki HR, Gaertner JH, Breyer-Pfaff U, Schied HW (1983) Neuroleptika: Grundlagen and Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka, Grundlagen and Therapie. Springer, Wien New York, S 203–300

    Google Scholar 

  • Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: A dopamine Di selective benznaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247: 1093–1102

    PubMed  CAS  Google Scholar 

  • Cichini G, Placheta P, Singer EA (1987) B-HT920 and B-HT958: Presynaptic effects on electrically evoked 3H-dopamine release from slices of rat nucleus accumbens. NaunynSchmiedebergs Arch Pharmacol 335: 28–31

    Article  CAS  Google Scholar 

  • Costall B, Domeney AM, Kelly ME, Naylor RJ, Tyers MB (1987) The antipsychotic potential of GR38032F, a selective antagonist of 5-HT3 receptors in the central nervous system. Br J Pharmacol 90: 89

    Google Scholar 

  • Da Prada M, Keller HH, Ketler R et al. (1982) Rol 1–1163, a specific and short acting MAO-inhibitor with antidepressant properties. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase-basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 183–196

    Google Scholar 

  • Delini-Stula A (1983) Pharmakologie der Antidepressiva. In: Langer G, Heiman H (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer, Wien New York, S 81–95

    Google Scholar 

  • Delini-Stula A, Hauser K, Bauman P, Olpe HR, Waldmeier P, Storni A (1982) Stereospecificity of behavioural and biochemical responses to oxaprotiline — a new antidepressant. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: Molecular mechanisms. Raven Press, New York, pp 265–275

    Google Scholar 

  • Delini-Stula A, Vassout A, Hauser K, Bittiger H, Buech O, Olpe HR (1983) Oxaprotiline and its enantiomers: Do they open new avenues in the research on the mode of action of antidepressants? In: Usdin E, Goldstein M, Friedhoff A, Georgotas A (eds) Frontiers in neuropsychiatry research. Macmillan, London pp 121–134

    Google Scholar 

  • Ebstein RP, Hermon M, Belmaker RH (1980) The effect of lithium on noradrenaline induced cyclic AMP accumulation in rat brain. Inhibition after chronic treatment and absence of supersensitivity. J Pharmacol Exp Ther 213: 161–167

    Google Scholar 

  • Emrich HM, Dose M, Zerssen D van (1984) Action of sodium valproate and of oxacarbazepine in patients with affective disorders. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Excerpta Medica, Amsterdam, pp 45–55

    Google Scholar 

  • Giannini AJ, Taraszewski R, Loiselle RH (1987) Verapamil and lithium in maintenance therapy of manic patients. J Clin Pharmacol 27: 980–982

    PubMed  CAS  Google Scholar 

  • Greil W (1981) Pharmakokinetik and Toxikologie des Lithiums. Bibl Psychiatr 161: 69–103

    PubMed  Google Scholar 

  • Greil W, Calker D van (1983) Lithium: Grundlagen und Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer, Wien New York, S 161–202

    Google Scholar 

  • Harrison-Read PE (1978) Models of lithium action based on behavioural studies using animals. In: Johnson FN, Johnson S (eds) Lithium in medical practice. MTP Press, Lancaster, pp 289–303

    Google Scholar 

  • Inhorn RC, Bansal VS, Majerus PW (1987) Pathway for inositol 1,3,4-trisphosphate and 1,4-bisphosphate metabolism. Proc Natl Acad Sci (USA) 84: 2170–2174

    Article  Google Scholar 

  • lorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226: 462–468

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693

    PubMed  CAS  Google Scholar 

  • Maître L, Baumann PA, Jaekel J, Waldmeier PC (1982) 5-HT uptake inhibitors: Psychopharmacological and neurobiochemical criteria of selectivity. In: Ho BT, Schoolar JC, Usdin E (eds) Serotonin in biological psychiatry. Adv Biochem Psychopharmacol 34: 229–246

    Google Scholar 

  • Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound ( Savoxepine ): Results of a pilot study. Pharmacopsychiatry 22: 38–41

    Google Scholar 

  • Mühlbauer HD, Müller-Oerlinghausen B (1985) Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: Further evidence for a central serotonergic action of lithium in man. J Neural Transm 61: 81–94

    Google Scholar 

  • Newman ME, Belmaker RH (1987) Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes of the cerebral cortex of the rat. Neuro-pharmacology 26: 211–217

    CAS  Google Scholar 

  • Okuma T (1984) Therapeutic and prophylactic efficacy of carbamazepine in manic depressive psychosis. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Excerpta Medica, Amsterdam, pp 76–87

    Google Scholar 

  • Olpe HR, Schellenberg A (1980) Reduced sensitivity of neurons to noradrenaline after chronic treatment with antidepressant drugs. Eur J Pharmacol 63: 7–13

    Article  PubMed  CAS  Google Scholar 

  • Porsolt RD, Bertin A, Jalfre M (1977) Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327–336

    Google Scholar 

  • Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379–391

    Google Scholar 

  • Schiwy H, Heath WR, Delini-Stula A (1989) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine — Results of dose-finding trials in depressed patients. J Neural Transm [Suppl] in press

    Google Scholar 

  • Schorderet M, Calanca A (1988) Neuroleptiques (antipsychotiques). In: Schorderet et al. (eds) Pharmacologie, des concepts fondamentaux aux applications thérapeutiques. Slatkine, Genève, pp 369–384

    Google Scholar 

  • Stefanis CN, Alevisos B, Papadimitriou G, Hatzimanolis J, Markianos M (1989) Clinical experience with a new monoamine oxidase inhibitor moclobemide (RO11–1163). Curr Med Res Opin 11: 65–72

    Google Scholar 

  • Sugrue MF (1981) Current concepts on the mechanism of action of antidepressant drugs. Pharmacol Ther 13: 219–247

    Article  PubMed  CAS  Google Scholar 

  • Sulser F (1978) Tricyclic antidepressants: Animal pharmacology. In: Iversen LL, Iversen SD, Snyder SH (eds) Affective disorders: Drug action in animal and man. Plenum Press, New York London, pp 157–197

    Google Scholar 

  • Thomsen K (1978) Renal handling of lithium at non-toxic and toxic serum lithium levels. A review. Dan Med Bull 25: 106–115

    PubMed  CAS  Google Scholar 

  • Vahora SA, Malek-Ahmadi P (1988) S-adenosylmethiomine in the treatment of depression. Neurosci Behav Rev 12: 139–141

    Article  CAS  Google Scholar 

  • Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257:495–496

    Google Scholar 

  • Waldmeier PC (1989) Mechanisms of action of lithium in affective disorders: A status report. Pharmacol Toxicol (in press)

    Google Scholar 

  • Waldmeier PR (1983) Neurobiochemische Wirkungen antidepressiver Substanzen. In: Langer G, Heimann H (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer, Wien New York, pp 65–81

    Google Scholar 

  • Waldmeier PC, Baumann PA, Hauser K, Maître L, Storni A (1982) Oxaprotiline, a nor-adrenaline uptake inhibitor with an active and an inactive enantiomer. Biochem Pharmacol 31: 2169–2176

    Article  PubMed  CAS  Google Scholar 

  • Waldmeier PC, Feiner AE, Tipton K (1983) The monoamine oxidase inhibiting properties of CGP 11 305 A. Eur J Pharmacol 94: 73–83

    Article  PubMed  CAS  Google Scholar 

  • Whitworth P, Kendall DA (1988) Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. J Neurochem 51: 258–265

    Article  PubMed  CAS  Google Scholar 

  • Wolfersdorf M, Wendt G, Binz U, Steiner B, Hole G (1988) CGP 12 103 A versus clomipramine in the treatment of depressed patients — Results of a double blind study. Pharmacopsychiatry 21: 203–207

    Article  PubMed  CAS  Google Scholar 

  • Wolff J (1979) Lithium interactions with the thyroid gland. In: Cooper TB, Gershon S, Kline NS, Schou M (eds) Lithium: Controversies and unresolved issues. Excerpta Medica, Amsterdam, pp 552–564

    Google Scholar 

  • Wood AJ, Goodwin GM (1987) A review of the biochemical and pharmacological actions of lithium. Psychol Med 17: 579–600

    Article  PubMed  CAS  Google Scholar 

  • Zohar J, Ebstein RP, Belmaker RH (1982) Adenylate cyclase as the therapeutic target site of lithium. In: Emrich HM, Aldenhoff JB, Lux HD (eds) Basic mechanisms in the action of lithium. Excerpta Medica, Amsterdam, pp 154–166

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CIBA-GEIGY AG, Postfach, CH-4002, Basel, Schweiz

    PD Dr. L. Maître

Authors
  1. PD Dr. L. Maître
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vorstand des Instituts für Rechtsmedizin, Ludwig-Maximilians-Universität München, Deutschland

    W. Spann

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Maître, L. (1990). Neuroleptika, Antidepressiva und Lithium — Synopsis und Perspektiven. In: Herz, A., Hippius, H., Spann, W. (eds) Psychopharmaka heute. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75004-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75004-5_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-51568-5

  • Online ISBN: 978-3-642-75004-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation